本帖最后由 老马 于 2012-1-13 21:20 编辑
/ G. y, I& a2 s: N
, v& {# z3 }3 Z5 X" B5 x3 X爱必妥和阿瓦斯丁的比较' `5 s. h8 D" h2 m8 z# \1 g
3 h# \) T5 H* ?$ uhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" }2 [" d3 H/ Z! `
- x0 N3 Y3 a9 W( Z/ \# ?0 o& C5 Z" F
% ?' \6 i: o* [http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/- O0 ?9 H* q& J6 Z* x
==================================================
# f* h( E% v0 a% ?8 J' ?% |Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), O5 E! v" d6 f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' u& M8 Z# b9 ^+ {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 y) [ ~! ^ v7 A* ~
|